EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Chronic Kidney Disease in France, Based on the EMPA-KIDNEY Clinical Trial

Harinala Groyer, Romain Supiot, Jean Tardu, Nicolas Virely, Marine Sivignon, Denis San, Pierre Lévy, Anastasia Ustyugova, Ziad A Massy

Clinical Drug Investigation · 2024-11 · 44 (11) · 811-828

DOI: 10.1007/s40261-024-01398-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Drug Investigation, online erschienen am 24.10.2024. Verfasst von Harinala Groyer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim, Paris, France. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Cost-Benefit Analysis, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim France.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesCost-Benefit AnalysisRenal Insufficiency, ChronicMarkov ChainsHumansFranceSodium-Glucose Transporter 2 InhibitorsFemaleMaleMiddle AgedAged

Substanzen

empagliflozinBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Boehringer Ingelheim, Paris, France.
  • Putnam, Paris, France. romain.supiot@putassoc.com.
  • Putnam, Paris, France.
  • Université Paris-Dauphine, Université PSL, LEDa (LEGOS), Paris, France.
  • Boehringer Ingelheim International GmbH, Ingelheim, Germany.
  • Paris and Department of Nephrology, Association Pour l'Utilisation du Rein Artificiel (AURA), Ambroise Paré University Medical Center, APHP, Paris, France.

Förderung

  • Boehringer Ingelheim France

Zitieren

APA

Groyer, H., Supiot, R., Tardu, J., Virely, N., Sivignon, M., San, D., Lévy, P., Ustyugova, A., & Massy, Z. A. (2024). Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Chronic Kidney Disease in France, Based on the EMPA-KIDNEY Clinical Trial. Clinical Drug Investigation, 44(11), 811-828. https://doi.org/10.1007/s40261-024-01398-4

Vancouver

Groyer H, Supiot R, Tardu J, Virely N, Sivignon M, San D, et al. Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Chronic Kidney Disease in France, Based on the EMPA-KIDNEY Clinical Trial. Clinical Drug Investigation. 2024;44(11):811-828. doi:10.1007/s40261-024-01398-4

BibTeX
@article{Groyer2024,
  author = {Groyer, Harinala and Supiot, Romain and Tardu, Jean and Virely, Nicolas and Sivignon, Marine and San, Denis and Lévy, Pierre and Ustyugova, Anastasia and Massy, Ziad A},
  title = {Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Chronic Kidney Disease in France, Based on the EMPA-KIDNEY Clinical Trial},
  journal = {Clinical Drug Investigation},
  year = {2024},
  volume = {44},
  number = {11},
  pages = {811--828},
  doi = {10.1007/s40261-024-01398-4}
}
Kostenlos starten →